Cellular Bi: Results From Allojoin Phase I
Edison | Apr 04, 2018 09:00AM ET
In March 2018, Cellular Bi (NASDAQ:CBMG) announced results from the Phase I study of AlloJoin for knee osteoarthritis (KOA). The primary endpoint was safety, and the adverse event (AE) profile was similar to previous studies, with pain and swelling as the primary effects. The company did not release detailed efficacy data, but it appears that the treatment effect was sustained for 48 weeks, and it appeared to stop cartilage degradation.
AlloJoin safe, but not without pain
The safety data from the Phase I trial did not show any serious adverse events (SAEs), or any AEs that would preclude the use of the treatment such as inflammatory reactions or neoplasias. However, half of the patients examined in the study had grade 3 pain (no grade 4 events were observed) and two patients did not complete the study due to pain. The pain remitted after treatment in five to 14 days, although efficacy will have to be sufficient to justify this patient hurdle.
To read the entire report Please click on the pdf File Below:
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.